Table 2.
Subgroup criteria | k | OR | 95% CI | p | Heterogeneity | |
---|---|---|---|---|---|---|
I2 | p | |||||
SGA/IUGR-group had a MD in GA < 0.5 weeks compared to control | 10 | 1.19 | 0.82–1.71 | 0.357 | 57% | 0.014 |
SGA/IUGR-group had a MD in GA ≥0.5 weeks compared to control | 8 | 0.60 | 0.41–0.89 | 0.010 | 16% | 0.303 |
SGA/IUGR-group did not differ significantly in GA from control (p ≥ 0.05) | 11 | 1.15 | 0.81–1.63 | 0.432 | 52% | 0.022 |
SGA/IUGR-group did differ significantly in GA from control (p < 0.05) | 7 | 0.58 | 0.38–0.87 | 0.009 | 24% | 0.244 |
All infants had GA ≤ 28 weeks or BW ≤ 1,000 g | 28 | 0.81 | 0.67–0.97 | 0.020 | 55% | <0.001 |
All infants were screened for PDA | 16 | 0.72 | 0.53–0.97 | 0.031 | 53% | 0.007 |
Presence of PDA was assessed in selected infants | 7 | 0.68 | 0.54–0.87 | 0.002 | 55% | 0.036 |
k: number of studies; OR: odds ratio; CI: confidence interval; SGA: small for gestational age; IUGR: intrauterine growth restriction; GA: gestational age; MD: mean difference; BW: birth weight; PDA: patent ductus arteriosus.